PortfoliosLab logo
ARCT vs. AMPH
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ARCT and AMPH is 0.31, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

ARCT vs. AMPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcturus Therapeutics Holdings Inc. (ARCT) and Amphastar Pharmaceuticals, Inc. (AMPH). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

ARCT:

-0.91

AMPH:

-0.99

Sortino Ratio

ARCT:

-1.49

AMPH:

-1.38

Omega Ratio

ARCT:

0.83

AMPH:

0.83

Calmar Ratio

ARCT:

-0.73

AMPH:

-0.60

Martin Ratio

ARCT:

-1.13

AMPH:

-1.26

Ulcer Index

ARCT:

59.39%

AMPH:

30.84%

Daily Std Dev

ARCT:

74.14%

AMPH:

39.69%

Max Drawdown

ARCT:

-92.79%

AMPH:

-64.63%

Current Drawdown

ARCT:

-89.87%

AMPH:

-60.45%

Fundamentals

Market Cap

ARCT:

$339.82M

AMPH:

$1.21B

EPS

ARCT:

-$2.52

AMPH:

$2.76

PS Ratio

ARCT:

2.37

AMPH:

1.65

PB Ratio

ARCT:

1.48

AMPH:

1.61

Total Revenue (TTM)

ARCT:

$135.17M

AMPH:

$728.26M

Gross Profit (TTM)

ARCT:

$136.31M

AMPH:

$365.89M

EBITDA (TTM)

ARCT:

-$60.17M

AMPH:

$240.52M

Returns By Period

In the year-to-date period, ARCT achieves a -26.16% return, which is significantly higher than AMPH's -30.76% return.


ARCT

YTD

-26.16%

1M

-2.19%

6M

-31.68%

1Y

-67.44%

3Y*

-14.26%

5Y*

-20.29%

10Y*

N/A

AMPH

YTD

-30.76%

1M

5.33%

6M

-43.11%

1Y

-39.00%

3Y*

-11.54%

5Y*

6.64%

10Y*

5.00%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Amphastar Pharmaceuticals, Inc.

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

ARCT vs. AMPH — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARCT
The Risk-Adjusted Performance Rank of ARCT is 99
Overall Rank
The Sharpe Ratio Rank of ARCT is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of ARCT is 55
Sortino Ratio Rank
The Omega Ratio Rank of ARCT is 88
Omega Ratio Rank
The Calmar Ratio Rank of ARCT is 77
Calmar Ratio Rank
The Martin Ratio Rank of ARCT is 2020
Martin Ratio Rank

AMPH
The Risk-Adjusted Performance Rank of AMPH is 99
Overall Rank
The Sharpe Ratio Rank of AMPH is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of AMPH is 77
Sortino Ratio Rank
The Omega Ratio Rank of AMPH is 77
Omega Ratio Rank
The Calmar Ratio Rank of AMPH is 1313
Calmar Ratio Rank
The Martin Ratio Rank of AMPH is 1414
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ARCT vs. AMPH - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and Amphastar Pharmaceuticals, Inc. (AMPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current ARCT Sharpe Ratio is -0.91, which is comparable to the AMPH Sharpe Ratio of -0.99. The chart below compares the historical Sharpe Ratios of ARCT and AMPH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

ARCT vs. AMPH - Dividend Comparison

Neither ARCT nor AMPH has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ARCT vs. AMPH - Drawdown Comparison

The maximum ARCT drawdown since its inception was -92.79%, which is greater than AMPH's maximum drawdown of -64.63%. Use the drawdown chart below to compare losses from any high point for ARCT and AMPH.


Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

ARCT vs. AMPH - Volatility Comparison

Arcturus Therapeutics Holdings Inc. (ARCT) has a higher volatility of 22.35% compared to Amphastar Pharmaceuticals, Inc. (AMPH) at 11.45%. This indicates that ARCT's price experiences larger fluctuations and is considered to be riskier than AMPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

ARCT vs. AMPH - Financials Comparison

This section allows you to compare key financial metrics between Arcturus Therapeutics Holdings Inc. and Amphastar Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20212022202320242025
29.38M
170.53M
(ARCT) Total Revenue
(AMPH) Total Revenue
Values in USD except per share items

ARCT vs. AMPH - Profitability Comparison

The chart below illustrates the profitability comparison between Arcturus Therapeutics Holdings Inc. and Amphastar Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-50.0%0.0%50.0%100.0%20212022202320242025
100.0%
50.0%
(ARCT) Gross Margin
(AMPH) Gross Margin
ARCT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Arcturus Therapeutics Holdings Inc. reported a gross profit of 29.38M and revenue of 29.38M. Therefore, the gross margin over that period was 100.0%.

AMPH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Amphastar Pharmaceuticals, Inc. reported a gross profit of 85.25M and revenue of 170.53M. Therefore, the gross margin over that period was 50.0%.

ARCT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Arcturus Therapeutics Holdings Inc. reported an operating income of -16.83M and revenue of 29.38M, resulting in an operating margin of -57.3%.

AMPH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Amphastar Pharmaceuticals, Inc. reported an operating income of 37.29M and revenue of 170.53M, resulting in an operating margin of 21.9%.

ARCT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Arcturus Therapeutics Holdings Inc. reported a net income of -14.08M and revenue of 29.38M, resulting in a net margin of -47.9%.

AMPH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Amphastar Pharmaceuticals, Inc. reported a net income of 25.29M and revenue of 170.53M, resulting in a net margin of 14.8%.